Injectable Particulated Human Acellular Dermal Matrix Booster for Skin Restoration: An Integrated Randomized, Split-Face, Double-Blinded Clinical Trial and Preclinical Study - PubMed
4 hours ago
- #regenerative medicine
- #dermal fillers
- #skin aging
- Injectable particulate human acellular dermal matrix (phADM) was evaluated as a facial skin booster in a randomized, split-face, double-blinded clinical trial.
- phADM showed greater improvements in skin density, volume, elasticity, wrinkle depth, pore area, hydration, and barrier-related parameters compared to hyaluronic acid (HA).
- Preclinical studies demonstrated phADM's ability to promote fibroblast infiltration, neocollagenesis, and extracellular matrix synthesis, along with anti-inflammatory and melanogenesis-suppressing effects.
- No serious adverse events were reported, indicating a favorable safety profile for phADM.
- phADM is presented as a restorative skin booster that supports durable dermis remodeling and functional rejuvenation.